Citations

Mayo Clinic

Clear

2717 citation(s) found for "Ma, Michelle".

Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)—A phase 2 study.
Younes, Anas , Santoro, Armando , Timmerman, John M. , Ansell, Stephen M. , Armand, Philippe , Fanale, Michelle A. , Ratanatharathorn, Voravit, Cohen, Jonathon B. , Kato, Kazunobu, Farsaci, Benedetto , Parker, Susan, Engert, Andreas , Santoro, Armando , Zinzani, Pier Luigi , Kuruvilla, John , Collins, Graham P. , Savage, Kerry J. , Trněný, Marek , Rodig, Scott J , Shipp, Margaret Ann

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7535-7535

10.1200/jco.2016.34.15_suppl.7535 Get It

Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).
Gounder, Mrinal M. , Mahoney, Michelle R., Tine, Brian Andrew Van, Ravi, Vinod , Attia, Steven , Deshpande, Hari A. , Conry, Robert M. , Movva, Sujana , Pishvaian, Michael J. , Crawford, Jeffrey , Sabagh, Tarek, Tap, William D. , Lefkowitz, Robert A. , Agaram, Narasimhan P. , Wright, John Joseph, Gupta, Abha A. , Milhem, Mohammed , Maki, Robert G. , Dueck, Amylou C. , Schwartz, Gary K.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11500-11500

10.1200/jco.2018.36.15_suppl.11500 Get It

Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.
Ross, Helen J. , Kozono, David , Urbanic, James J., DuFrane, Carter, Bāra, Ilze, Gandhi, Mayank , Schulze, Katja , Brockman, Jane Michelle, Wang, Xiaofei F., Stinchcombe, Tom, Kozono, David E , Williams, Terence M. , Vokes, Everett E. , Stinchcombe, Thomas E.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS8585-TPS8585

10.1200/jco.2018.36.15_suppl.tps8585 Get It

Association between treatment facility volume and mortality in patients with glioblastoma (GBM): A large national analysis.
DeDeo, Michelle , Free, Joseph, Berdeguez, Kyle, Rosenfeld, Steven S. , Quiñones‐Hinojosa, Alfredo , Chanan‐Khan, Asher , Aulakh, Sonikpreet , Ailawadhi, Sikander

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 2026-2026

10.1200/jco.2018.36.15_suppl.2026 Get It

Creation and validation of the “myMPN” prospective patient registry of myeloproliferative neoplasm patients.
Scherber, Robyn M. , Whyte, Lindsey, Woehrle, Michelle, Harrison, Claire , Dueck, Amylou C. , Verstovšek, Srđan , Mesa, Ruben A.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e19031-e19031

10.1200/jco.2018.36.15_suppl.e19031 Get It

A Prognostic Index to Identify the Risk of Developing Depression Symptoms Among U.S. Medical Students Derived From a National, Four-Year Longitudinal Study
Wittlin, Natalie M. , Yeazel, Mark W. , Burke, Sara E. , Cunningham, Brooke A. , Ryn, Michelle van , Dyrbye, Liselotte N. , van Ryn, Michelle , Hardeman, Rachel R. , Herrin, Jeph , Dovidio, John F. , Phelan, Sean M. , Shanafelt, Tait D.

Academic Medicine | September 5, 2018 | Volume: 94 | Issue: 2 | Pages: 217-226

10.1097/acm.0000000000002437 | PMID 30188367 Get It

Purpose To determine baseline individual and school-related factors associated with increased risk of developing depression symptoms by year four (Y4) of medical school, and to develop a prognostic index that stratifies risk of developing depression symptoms (Depression-PI) among medical students. Method The authors analyzed data from 3,743 students (79% of 4,732) attending 49 U.S. medical schools who completed baseline (2010) and Y4 (2014) surveys. Surveys included validated scales measuring depression, stress, coping, and social support. The authors collected demographics and school characteristics and conducted multivariate analysis to identify baseline factors independently associated with Y4 depression symptoms. They used these factors to create a prognostic index for developing depression. They randomly divided the data into discovery (n = 2,455) and replication (n = 1,288) datasets and calculated c statistics ( c ). Results The authors identified eight independent prognostic factors for experiencing depression symptoms during training within the discovery dataset: age; race; ethnicity; tuition; and baseline depression symptoms, stress, coping behaviors, and social support. The Depression-PI stratified four risk groups. Compared with the low risk group, those in the intermediate, high, and very high risk groups had an odds ratio of developing depression of, respectively, 1.75, 3.98, and 9.19 ( c = 0.71). The replication dataset confirmed the risk groups. Conclusions Demographics; tuition; and baseline depression symptoms, stress, coping behaviors, and social support are independently associated with risk of developing depression during training among U.S. medical students. By stratifying students into four risk groups, the Depression-PI may allow for a tiered primary prevention approach.
Multiple isodicentric Y chromosomes in myeloid malignancies: a unique cytogenetic entity and potential therapeutic target
Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Oliver, Gavin R. , Rao, Kathleen W., Kaiser‐Rogers, Kathleen, Davila, Jaime , Fadra, Numrah, Wehrs, Rebecca N., Elliott, Michelle A. , Greipp, Patricia T. , Halling, Kevin C. , Dyke, Daniel L. Van , Davila, Jaime I, Van Dyke, Daniel L, Greipp, Patricia T , Davila, Jaime I

Leukemia & Lymphoma | August 30, 2018 | Volume: 60 | Issue: 3 | Pages: 821-824

10.1080/10428194.2018.1498492 | PMID 30160574 Get It

Statins and Brain Health: Alzheimer’s Disease and Cerebrovascular Disease Biomarkers in Older Adults
Przybelski, Scott A. , Graff‐Radford, Jonathan , Castillo, Anna , Lowe, Val J. , Mielke, Michelle M. , Roberts, Rosebud O., Jack, Clifford R. , Petersen, Ronald C. , Vemuri, Prashanthi , Castillo, Anna M, Jack, Clifford R , Mielke, Michelle M , Vemuri, Prashanthi , Castillo, Anna M , Ramanan, Vijay K. , Reid, Robert I. , Knopman, David S.

Journal of Alzheimer’s Disease | August 24, 2018 | Volume: 65 | Issue: 4 | Pages: 1345-1352

10.3233/jad-180446 | PMID 30149450 Get It

Background: Statins have been proposed to reduce the risk of Alzheimer’s disease (AD). Objective: Assess whether long-term statin use was associated with neuroimaging biomarkers of aging and dementia. Methods: Methods: We analyzed neuroimaging biomarkers in 1,160 individuals aged 65+ from the Mayo Clinic Study of Aging, a population-based prospective longitudinal study of cognitive aging. Results: Statin-treated (5+ years of therapy) individuals had greater burden of mid-and late-life cardiovascular disease ( p < 0.001) than statin-untreated (≤3 months) individuals. Lower fractional anisotropy in the genu of the corpus callosum, an early marker of cerebrovascular disease, was associated with long-term statin exposure ( p < 0.035). No significant associations were identified between long-term statin exposure and cerebral amyloid or tau burden, AD pattern neurodegeneration, or white matter hyperintensity burden. Conclusions: Long-term statin therapy was not associated with differences in AD biomarkers. Individuals with long-term statin exposure had worse white matter integrity in the genu of the corpus callosum, consistent with the coexistence of higher cerebrovascular risk factor burden in this group.
rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology
Kelemen, Linda E. , Earp, Madalene A. , Chenevix‐Trench, Georgia , Group, On behalf of Australian Ovarian Cancer Study, Fasching, Peter A. , Beckmann, Matthias W. , Ekici, Arif B. , Hein, Alexander , Lambrechts, Diether , Lambrechts, Sandrina, Nieuwenhuysen, Els Van , Vergote, Ignace , Rossing, Mary Anne, Chang‐Claude, Jenny , Moysich, Kirsten, Cannioto, Rikki , Lele, Shashikant , Odunsi, Kunle , Goodman, Marc T. , Shvetsov, Yurii B. , Thompson, Pamela J., Dörk, Thilo , Antonenkova, Natalia, Bogdanova, Natalia , Hillemanns, Peter , Runnebaum, Ingo B. , Harter, Philipp , Heitz, Florian , Schwaab, Ira, Edwards, Robert P., Kelley, Joseph L., Ness, Roberta B., Lester, Jenny, Oršulić, Sandra , Walsh, Christine M. , Jensen, Allan , Cunningham, Julie M. , Vierkant, Robert A. , Bruinsma, Fiona , Hildebrandt, Michelle, Liang, Dong , Lu, Karen H., Wu, Xifeng , Sellers, Thomas A. , Schildkraut, Joellen M. , Iversen, Edwin S., Terry, Kathryn L. , Tworoger, Shelley S. , Thomsen, Liv Vestrheim, Krakstad, Camilla , Tangen, Ingvild L. , Aben, Katja K.H. , Massuger, Leon F.A.G. , Altena, Anne M. van , Bean, Yukie T., Kellar, Melissa, Le, Nhu D. , Brooks‐Wilson, Angela , Jakubowska, Anna , Lubiński, Jan , Wentzensen, Nicolas , Brinton, Louise A. , Lissowska, Jolanta , Høgdall, Estrid , Engelholm, Svend Aage, Høgdall, Claus , Lundvall, Lene, Nedergaard, Lotte , Dicks, Ed , Song, Honglin , McNeish, Iain A. , Carty, Karen , Eccles, Diana , Whittemore, Alice S. , McGuire, Valerie , Rothstein, Joseph H. , Sieh, Weiva , Narod, Steven A., Phelan, Catherine, McLaughlin, John, Ziogas, Argyrios, Menon, Usha , Gayther, Simon A. , Ramus, Susan J. , Wu, Anna H. , Pearce, Celeste Leigh, Lee, Alice W. , Pike, Malcolm C. , Kupryjańczyk, Jolanta , Podgórska, Agnieszka , Plisiecka-Hałasa, Joanna, Sawicki, Włodzimierz , Goode, Ellen L. , Berchuck, Andrew, Lu, Karen H. , Lambrechts, Diether , Earp, Madalene, Hein, Alexander , Behrens, Sabine , Hillemanns, Peter , Nevanlinna, H , Kjaer, Susanne K , Jensen, Allan , Cunningham, Julie M , Vierkant, Robert A , Bjorge, Line , Gronwald, Jacek , Brinton, Louise A , Pharoah, Paul D P , Tyrer, Jonathan P. , McNeish, Iain A , Eccles, Diana , Menon, Usha , Ramus, Susan J , Dörk, Thilo , Lambrechts, Diether , Tworoger, Shelley S , Moysich, Kirsten , Lissowska, Jolanta , Brooks-Wilson, Angela R , Heitz, Florian , Jakubowska, Anna , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Ekici, Arif B , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Lubinski, Jan , Goodman, Marc T , Fridley, Brooke L. , Group, On behalf of Australian Ovarian Cancer Study, Doherty, Jennifer A. , Behrens, Sabine , Moysich, Kirsten B. , Wilkens, Lynne R. , Bois, Andreas du , Bützow, Ralf C. , Pelttari, Liisa M. , Nevanlinna, Heli , Modugno, Francesmary , Karlan, Beth Y. , Walsh, Christine, Kjær, Susanne K. , Giles, Graham G. , Southey, Melissa C. , Levine, Douglas A. , Cramer, Daniel W. , Poole, Elizabeth M. , Bandera, Elisa V. , Olson, Sara H. , Orlow, Irene , Thomsen, Liv Cecilie Vestrheim , Bjørge, Line , Kiemeney, Lambertus A. , Pejovic, Tanja B. , Cook, Linda S. , Gronwald, Jacek , Cybulski, Cezary , Pharoah, Paul D.P. , Siddiqui, Nadeem , Glasspool, Rosalind , Paul, James , Campbell, Ian , McLaughlin, John, Risch, Harvey A. , Anton‐Culver, Hoda , Gentry‐Maharaj, Aleksandra

International Journal of Molecular Sciences | August 21, 2018 | Volume: 19 | Issue: 9 | Pages: 2473

10.3390/ijms19092473 | PMID 30134598 Get It

Thymidylate synthase (TYMS) is a crucial enzyme for DNA synthesis. TYMS expression is regulated by its antisense mRNA, ENOSF1. Disrupted regulation may promote uncontrolled DNA synthesis and tumor growth. We sought to replicate our previously reported association between rs495139 in the TYMS-ENOSF1 3′ gene region and increased risk of mucinous ovarian carcinoma (MOC) in an independent sample. Genotypes from 24,351 controls to 15,000 women with invasive OC, including 665 MOC, were available. We estimated per-allele odds ratios (OR) and 95% confidence intervals (CI) using unconditional logistic regression, and meta-analysis when combining these data with our previous report. The association between rs495139 and MOC was not significant in the independent sample (OR = 1.09; 95% CI = 0.97–1.22; p = 0.15; N = 665 cases). Meta-analysis suggested a weak association (OR = 1.13; 95% CI = 1.03–1.24; p = 0.01; N = 1019 cases). No significant association with risk of other OC histologic types was observed (p = 0.05 for tumor heterogeneity). In expression quantitative trait locus (eQTL) analysis, the rs495139 allele was positively associated with ENOSF1 mRNA expression in normal tissues of the gastrointestinal system, particularly esophageal mucosa (r = 0.51, p = 1.7 × 10−28), and nonsignificantly in five MOC tumors. The association results, along with inconclusive tumor eQTL findings, suggest that a true effect of rs495139 might be small.